Antihypertensives Market To 2016 By: GBI Research | - In 2009, the global anti-hypertensive market was estimated to be worth $27.2 billion, representing a Compound Annual Growth Rate (CAGR) of 5.0% between 2002 and 2009. The market is forecast to reach $30 billion by 2016, indicating a CAGR of 1.5% between 2009 and 2016. The primary reason for slight and gradual growth in the market is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2007.
Patent Strategies By: GBI Research | - The pharmaceutical industry is going to experience major patent expiries during 2010-2014, of which 2010 to 2012 are expected to be peak years, with the loss of patents for drugs whose sales were more than $60 billion during 2009.
In 2010, major drugs like Lipitor, Cozaar, Advair, Arimidex, Flomax and Gemzar, with combined sales revenues of more than $24 billion, are expected to face generic competition. In 2011, nine drugs of six companies are going to experience a major impact of ... Tags:Patent Strategies, Product Lifecycles, Generics Markets
Hypertension: Competing Treatments And Market Entry Considerations By: Vision Shopsters | - This report presents the findings of a global survey on current treatments and prescribing practices for Hypertension. These findings were made following the participation of more than 280 clinics worldwide, which provided detailed information of their treatment practices.
Today, approximately 1 billion people worldwide have high blood pressure, a figure expected to increase to 1.5 billion by 2025, affecting 1 in 3 adults over the age of 20 (Lancet. 2005;365:217-223). Hypertension i ... Tags:Competing, Considerations, Entry, hypertension, Market
